Josh Coughlin

President & Chief Executive Officer

Mr. Coughlin has been the President and Chief Executive Officer of Benovus Bio since the company's inception in the first quarter of 2012. Prior to Benovus Bio, Mr. Coughlin was the President of Quantum Immunologics (“QI”), a privately held early stage biotech company focused on developing individualized immunotherapy products for cancer patients. Under Mr. Coughlin’s direction, QI completed a Phase I/IIa trial for Stage IV Breast Cancer patients leading to a successful end of phase meeting with the FDA, which subsequently lead to QI’s assets being acquired by Benovus Bio. Mr. Coughlin holds a BA in Economics and Psychology from Indiana University, where he graduated Phi Beta Kappa. In addition, Mr. Coughlin earned his Master’s in Business Administration from the University of Chicago.

Tam Jackson, RN, BSN

Director, Clinical Operations

Mrs. Jackson is a licensed nurse with over 20 years of Oncology nursing experience, including 17 years in Clinical Research. Mrs. Jackson started her clinical research experience as a Research Nurse at the Cancer Therapeutic and Research Center (CTRC) in San Antonio, TX managing Phase I-IIa clinical trials for large pharmaceutical companies. Subsequently, Mrs. Jackson progressed on to manage all aspects of clinical trial operations for Phase II and Phase III trials, including development of Standard Operations Procedures (SOPs). In addition, Mrs. Jackson has been involved in protocol development, IND submissions, and regulatory compliance and safety committees. She has worked on behalf of small and large pharmaceutical companies, including Johnson and Johnson, Bayer, Allos Therapeutices and numerous Clinical Research Organizations (CROs). Mrs. Jackson holds a BS in Nursing from The University of Texas Health Science Center in San Antonio, Texas (UTHSC-SA).